This study aimed to elucidate the clinical utility of HER2-targeted PET/CT imaging for patients with breast cancer, with a particular focus on dissecting the correlation between PET/CT outcomes and response evaluation. This evidence concerns the gene ERBB2 and breast carcinoma.